Concept

peg-IFN-λ1 Treatment Protects Lung Function in Mice Infected with SARS-CoV-2 MA

Pegylated human interferon lambda-1 (peg-IFN-λ1) is an antiviral drug that is currently in phase-3 of development that could be used to treat COVID-19 patients. 1-year old BALB/c mice were treated with 2µg peg-IFN-λ1 18 hours before or 12 hours after infection with SARS-CoV-2 MA. It was demonstrated that both prophylactic and therapeutic administration of peg-IFN-λ1 protected lung function (as demonstrated by PenH and Rpef).

Image 0

0

1

Updated 2020-09-06

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences